Ruxolitinib in Patients With Breast Cancer
NCT01562873
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
21
Enrollment
OTHER
Sponsor class
Stopped
Not enough responses to continue treatment.
Conditions
Breast Cancer
Interventions
DRUG:
Ruxolitinib
Sponsor
Dana-Farber Cancer Institute